Safety studies on intravenous infusion of a potent angiogenesis inhibitor: taurocholate-conjugated low molecular weight heparin derivative LHT7 in preclinical models

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273–86.
   PubMed Web of Science ®Google Scholar
• Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60:222–43.
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389–95.
   PubMed Web of Science ®Google Scholar
• Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9:604–13.
   PubMed Web of Science ®Google Scholar
• Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003;112:1142–51.
   PubMed Web of Science ®Google Scholar
• Pietras K, Sjoblom T, Rubin K, et al. PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439–43.
   PubMed Web of Science ®Google Scholar
• Debergh I, Van Damme N, Pattyn P, et al. The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model. Br J Cancer 2010;102:837–43.
   PubMed Web of Science ®Google Scholar
• Capila I, Linhardt RJ. Heparin–protein interactions. Angew Chem Int Ed Engl 2002;41:391–412.
   PubMed Web of Science ®Google Scholar
• Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140–8.
   PubMed Web of Science ®Google Scholar
• Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002;2:521–8.
   PubMed Web of Science ®Google Scholar
• Mousa SA. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Semin Thromb Hemost 2007;33:524–33.
   PubMed Web of Science ®Google Scholar
• Mousa SA, Linhardt R, Francis JL, Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 2006;96:816–21.
   PubMed Web of Science ®Google Scholar
• Pisano C, Aulicino C, Vesci L, et al. Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 2005;15:1C–6C.
   PubMed Web of Science ®Google Scholar
• Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs 2008;17:1769–76.
   PubMed Web of Science ®Google Scholar
• Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475–85.
   PubMed Web of Science ®Google Scholar
• Mammadov R, Mammadov B, Toksoz S, et al. Heparin mimetic peptide nanofibers promote angiogenesis. Biomacromolecules 2011;12:3508–19.
   PubMed Web of Science ®Google Scholar
• Lee JK, Choi B, Sobel RA, et al. Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. J Neurosurg 1990;73:429–35.
   PubMed Web of Science ®Google Scholar
• Lee JH, Canny MD, De Erkenez A, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA 2005;102:18902–7.
   PubMed Web of Science ®Google Scholar
• Klagsbrun M. Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. Semin Cancer Biol 1992;3:81–7.
   PubMedGoogle Scholar
• Lee E, Kim YS, Bae SM, et al. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. Int J Cancer 2009;124:2755–65.
   PubMed Web of Science ®Google Scholar
• Chung SW, Lee M, Bae SM, et al. Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge. Biomaterials 2012;33:9070–9.
   PubMed Web of Science ®Google Scholar
• Alam F, Al-Hilal TA, Chung SW, et al. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. Biomaterials 2014;35:6543–52.
   PubMed Web of Science ®Google Scholar
• Alam F, Al-Hilal TA, Chung SW, et al. Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy. J Control Release 2015;197:180–9.
   PubMed Web of Science ®Google Scholar
• Alam F, Chung SW, Hwang SR, et al. Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor. J Appl Toxicol 2014;35:104–15.
   PubMed Web of Science ®Google Scholar
• Liu J, Kraut EH, Balcerzak S, et al. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat. Cancer Chemother Pharmacol 2002;50:445–53.
   PubMed Web of Science ®Google Scholar
• Wang SL, Chang YT. Discovery of heparin chemosensors through diversity oriented fluorescence library approach. Chem Commun 2008;(10):1173–5.
   PubMed Web of Science ®Google Scholar
• Adulnirath A, Chung SW, Park J, et al. Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor. J Control Release 2012;164:8–16.
   PubMed Web of Science ®Google Scholar
• Fehr M, Catschegn S, Reinhart WH, et al. The influence of bevacizumab on platelet function. Swiss Med Wkly 2011;141:132–43.
   Web of Science ®Google Scholar
• Sobolewska B, Grimmel C, Gatsiou A, et al. Different effects of ranibizumab and bevacizumab on platelet activation profile. Ophthalmologica 2015;234:195–210.
   PubMed Web of Science ®Google Scholar
• Greenlee H, Balneaves LG, Carlson LE, et al. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. JNCI Monographs 2014;50:346–58.
   Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391–400.
   PubMed Web of Science ®Google Scholar